Tozinameran Other names: BNT162b2

Active ingredient description

The nucleoside-modified messenger RNA in COVID-19 mRNA Vaccine BNT162b2 is formulated in lipid nanoparticles, which enable delivery of the RNA into host cells to allow expression of the SARS-CoV-2 S antigen. The vaccine elicits both neutralizing antibody and cellular immune responses to the spike (S) antigen, which may contribute to protection against COVID-19 disease.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code Group title Classification
J07BN01 J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BN Covid-19 vaccines
Discover more medicines within J07BN01

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title Information Source Document Type  
PFIZER-BIONTECH COVID-19 VACCINE BNT162b2 Suspension for injection FDA, National Drug Code (US) MPI, US: SPL/PLR
COVID-19 mRNA VACCINE BNT162b2 Concentrate for solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
COMIRNATY Concentrate for dispersion for injection European Medicines Agency (EU) MPI, EU: SmPC

External identifiers

CAS Substance: 2417899-77-3
DrugBank Drug: DB15696
KEGG Drug: D11971
RxNorm Ingredient: 2468235
UNII Identifier: 5085ZFP6SJ
TOZINAMERAN

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.